#None #Amgen #Lung Cancer #IMDYLLTRA

European Commission Approves IMDYLLTRA® for Small Cell Lung Cancer

On June 3, 2026, Amgen announced that the European Commission has granted marketing authorization for its innovative drug IMDYLLTRA® (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line platinum-based chemotherapy. This pivotal approval marks a significant advancement in oncological care within Europe.

Significance of IMDYLLTRA®

IMDYLLTRA® is notable as it is the first and only therapy classified as a T-cell engager that has been approved for this aggressive form of lung cancer, which is known for its high recurrence rate and limited treatment options after initial chemotherapy failure. Jean-Charles Soria, Senior Vice President of Oncology at Amgen, explained, “Small cell lung cancer is one of the most aggressive solid tumors, characterized by high relapse rates post-first-line treatment and limited therapeutic avenues.”

The approval was primarily based on the results from the Phase III DeLLphi-304 clinical trial, which demonstrated that IMDYLLTRA® significantly improves overall survival compared to standard chemotherapy, indicating a remarkable 40% reduction in the risk of death among treated patients.

Clinical Trial Results

In the DeLLphi-304 trial, which included 509 patients diagnosed with ES-SCLC who had progressed after one line of platinum-based chemotherapy, the use of IMDYLLTRA® resulted in an increased median overall survival by more than five months compared to the standard treatment (13.6 months versus 8.3 months). The data supports the drug’s efficacy and opens avenues for vital treatment for this deadly illness.

Implications for Patients

Patients with ES-SCLC had faced dire circumstances upon progression after initial chemotherapy, often surviving only a few months. Debra Montague, President of Lung Cancer Europe (LuCE), stated, “Approval of a new therapeutic option for individuals living with this difficult cancer in Europe is a significant advance and underscores the urgent need for innovation in lung cancer treatment.”

Safety and Side Effects

The safety profile of IMDYLLTRA® aligns with previous findings, demonstrating no significant new risks. However, common side effects include cytokine release syndrome (CRS), decreased appetite, fever, taste disturbances, fatigue, and anemia. Notably, CRS, which occurred in 56.7% of patients, requires careful monitoring, especially in the first few doses, aiming to proactively manage symptoms.

Future Directions

Amgen has pursued an extensive clinical program for IMDYLLTRA®, assessing its performance not only in monotherapy but also in combination therapies, exploring possibilities in earlier SCLC stages as well as in relapsed treatment settings. Such comprehensive research could reshape future protocols in oncological therapy, providing patients with new hope.

In conclusion, the European Commission's approval of IMDYLLTRA® marks a landmark moment in the treatment landscape for ES-SCLC, allowing patients better access to an innovative cancer therapy that significantly enhances survival outcomes. This approval reflects Amgen's commitment to developing groundbreaking medications that can substantially improve treatment results and patient lives in the fight against aggressive cancers.


For more information regarding IMDYLLTRA® and ongoing clinical trials, you may visit www.tarlatamabclinicaltrials.com and also refer to Amgen's official communications.